Dronedarone hydrochloride enhances the bioactivity of endothelial progenitor cells via regulation of the AKT signaling pathway
Jian Zhang1,#, Thi Hong Van Le1,#, Vinoth Kumar Rethineswaran1, Yeon-Ju Kim1, Woong Bi Jang1, Seung Taek Ji1, Thanh Truong Giang Ly1, Jong Seong Ha1, Jisoo Yun1, Jae Hun Cheong2, Jinsup Jung3,*, and Sang-Mo Kwon1,3,*
1Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612,2Department of Molecular Biology, Pusan National University, Busan 46241, 3Department of Physiology, School of Medicine, Pusan National University, Yangsan 50612, Korea
Cardiovascular disease (CVD) and its complications are the leading cause of morbidity and mortality in the world. Because of the side effects and incomplete recovery from current therapy, stem cell therapy emerges as a potential therapy for CVD treatment, and endothelial progenitor cell (EPC) is one of the key stem cells used for therapeutic applications. The effect of this therapy required the expansion of EPC function. To enhance the EPC activation, proliferation, and angiogenesis using dronedarone hydrochloride (DH) is the purpose of this study. DH received approval for atrial fibrillation treatment and its cardiovascular protective effects were already reported. In this study, DH significantly increased EPC proliferation, tube formation, migration, and maintained EPCs surface marker expression. In addition, DH treatment up-regulated the phosphorylation of AKT and reduced the reactive oxygen species production. In summary, the cell priming by DH considerably improved the functional activity of EPCs, and the use of which might be a novel strategy for CVD treatment.